BMW to Launch Direct Sales Model in Europe Next Year
By Andrea Figueras
BMW plans to start selling vehicles directly to customers across Europe starting next year, following the model pioneered by electric-vehicle maker Tesla.
The German luxury car maker said Wednesday that it will introduce the model in different stages, starting on Jan. 1 for its Mini brand in Italy, Poland and Sweden, gradually followed by the remaining European countries.
The BMW brand is expected to transition to the direct-to-consumer model from 2026, it said.
The new model seeks to standardize pricing for identical vehicle models and communicate directly with its customers, the company said.
The company said its European retail partners approved the move, with agency contracts signed by all Mini partners. Retailers will earn a fixed commission per car sold, the company said.
BMW also said that it will digitalize the purchase process and customers will be able to choose between online and physical purchases.
Write to Andrea Figueras at andrea.figueras@wsj.com
(END) Dow Jones Newswires
October 18, 2023 05:11 ET (09:11 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track